A

Aileron Therapeutics Inc
NASDAQ:ALRN

Watchlist Manager
Aileron Therapeutics Inc
NASDAQ:ALRN
Watchlist
Price: 1.75 USD -0.57% Market Closed
Market Cap: 37.9m USD
Have any thoughts about
Aileron Therapeutics Inc?
Write Note

Aileron Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aileron Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
A
Aileron Therapeutics Inc
NASDAQ:ALRN
Research & Development
-$12.9m
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%
No Stocks Found

Aileron Therapeutics Inc
Glance View

Market Cap
37.9m USD
Industry
Biotechnology

Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2017-06-29. The firm is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual inhibitor, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focuses on treating patients with p53-mutated cancers. The company is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced toxicities. The company stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. Its platform enables it to chemically stabilize and improve the activity of a range of alpha-helical peptides. ALRN-6924 can pause cell division in cells with wild type (WT), p53, including normal bone marrow cells, and ALRN-6924 has no activity against cancer cells with mutations in p53.

ALRN Intrinsic Value
0.81 USD
Overvaluation 53%
Intrinsic Value
Price
A

See Also

What is Aileron Therapeutics Inc's Research & Development?
Research & Development
-12.9m USD

Based on the financial report for Sep 30, 2024, Aileron Therapeutics Inc's Research & Development amounts to -12.9m USD.

What is Aileron Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
5%

Over the last year, the Research & Development growth was -190%. The average annual Research & Development growth rates for Aileron Therapeutics Inc have been 4% over the past three years , 5% over the past five years .

Back to Top